Immune modulation for cancer therapy-Reference-Cited by-同舟云学术

Immune modulation for cancer therapy

Published:2014-09-11 Issue:12 Volume:111 Page:2214-2219
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Naidoo J,Page D B,Wolchok J D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014348.pdf

Reference39 articles.

1. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31 (33): 4199–4206.

2. Avogadri F, Yuan J, Yang A, Schaer D, Wolchok JD (2011) Modulation of CTLA-4 and GITR for cancer immunotherapy. Curr Top Microbiol Immunol 344: 211–244.

3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (26): 2455–2465.

4. Callahan MK HC, Curran MA (2013) Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4358) and ipilimumab. The Annual Meeting of the American Society of Clinical Oncology, Chicago, USA. J Clin Oncol 31 (Suppl): abstr 3003.

5. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD (2013) OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73 (24): 7189–7198.

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review;Frontiers in Immunology;2024-08-27

2. From Oral Health to Obstetric Outcomes: A Comprehensive Review of Periodontal Disease and Its Implications for Preeclampsia;Cureus;2024-06-23

3. The Complex Connection between Obesity and Cancer: Signaling Pathways and Therapeutic Implications;Nutrition and Cancer;2024-06-07

4. A Snapshot of Selenium-enclosed Nanoparticles for the Management of Cancer;Current Pharmaceutical Design;2024-03